{
    "organizations": [],
    "uuid": "c5f1dc0709bf08060cfebadf9a0052996f840709",
    "author": "",
    "url": "https://www.reuters.com/article/brief-novartis-says-data-reinforces-cose/brief-novartis-says-data-reinforces-cosentyx-effectiveness-idUSFWN1PB014",
    "ord_in_thread": 0,
    "title": "BRIEF-Novartis says data reinforces ‍Cosentyx effectiveness",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 16 (Reuters) - Novartis AG:\n* NOVARTIS NEW DATA REINFORCES SUPERIORITY OF COSENTYX® VERSUS STELARA®* IN ACHIEVING SKIN CLEARANCE FOR PSORIASIS PATIENTS\n* ‍CLARITY STUDY SHOW COSENTYX(®) (SECUKINUMAB) WAS SIGNIFICANTLY MORE EFFECTIVE THAN STELARA(®*) (USTEKINUMAB) IN DELIVERING CLEAR AND ALMOST CLEAR SKIN AT 12 WEEKS AND AT 16 WEEKS​\n* ‍COSENTYX CONTINUED TO HAVE A FAVORABLE AND CONSISTENT SAFETY PROFILE​ Source text for Eikon: Further company coverage: (Reporting By Michael Shields)\n ",
    "published": "2018-01-16T08:19:00.000+02:00",
    "crawled": "2018-01-16T08:38:59.017+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "novartis",
        "ag",
        "novartis",
        "new",
        "data",
        "reinforces",
        "superiority",
        "versus",
        "achieving",
        "skin",
        "clearance",
        "psoriasis",
        "patient",
        "study",
        "show",
        "cosentyx",
        "secukinumab",
        "significantly",
        "effective",
        "stelara",
        "ustekinumab",
        "delivering",
        "clear",
        "almost",
        "clear",
        "skin",
        "week",
        "continued",
        "favorable",
        "consistent",
        "safety",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "michael",
        "shield"
    ]
}